-
-
-
-
-
-
-
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
The Next Generation of the GLP-1 Revolution Is Already Underway
-
-
-
-
-
-
-
PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
-
-
-
-
-
-
-
Pfizer weight-loss drug data raises questions about side effects, shares fall
-
-
-
-
-
-
-
Quanterix names Everett Cunningham as new president and CEO
-
-
-
-
-
-
-
Pfizer provides 2026 financial guidance with lower revenue and earnings outlook
-
-
-
-
-
-
-
Pfizer amends merger deal with Metsera, raising value to $86.25 per share
-
1,200,803 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


